Skip to main content

Table 1 Baseline demographic and anthropometric characteristics in the overall population

From: A post-hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes-related quality measures

 

CANA 100 mg (N = 483)

CANA 300 mg (N = 485)

GLIM (N = 482)

Sex, n (%)

 Male

252 (52.2)

241 (49.7)

263 (54.6)

 Female

231 (47.8)

244 (50.3)

219 (45.4)

Age (years)

 Category, n (%)

  <65

397 (82.2)

411 (84.7)

399 (82.8)

  ≥65

86 (17.8)

74 (15.3)

83 (17.2)

  Mean (SD)

56.4 (9.49)

55.8 (9.17)

56.3 (9.01)

Race, n (%)

 White

323 (66.9)

333 (68.7)

322 (66.8)

 Black/African American

20 (4.1)

18 (3.7)

22 (4.6)

 Asian

99 (20.5)

93 (19.2)

93 (19.3)

 Other

41 (8.4)

41 (8.5)

45 (9.3)

Ethnicity, n (%)

 Hispanic/Latino

86 (17.8)

80 (16.5)

76 (15.8)

 Not Hispanic/Latino

395 (81.8)

404 (83.3)

403 (83.6)

 Not reported

1 (0.2)

1 (0.2)

1 (0.2)

 Unknown

1 (0.2)

0 (0)

2 (0.4)

Body weight (kg)

 Mean (SD)

86.9 (20.06)

86.6 (19.48)

86.5 (19.82)

BMI (kg/m2), n (%)

 <30

215 (44.5)

224 (46.2)

234 (48.5)

 ≥30

268 (55.5)

261 (53.8)

248 (51.5)

 Mean (SD)

31.0 (5.29)

31.2 (5.39)

30.9 (5.54)

  1. BMI body mass index, CANA canagliflozin, GLIM glimepiride, SD standard deviation